We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

73 hedge funds and large institutions have $286M invested in Tetraphase Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

29% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 17

14% more funds holding

Funds holding: 64 → 73 (+9)

2% less capital inflows, than outflows

Capital inflows: $43.1M | Capital outflows: $44M

6% less call options, than puts

Call options by funds: $2.16M | Put options by funds: $2.29M

8.3% less ownership

Funds ownership: 55.03% → 46.73% (-8.3%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
73
Holders Change
+9
Holders Change %
+14.06%
% of All Funds
2.11%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
17
Increased
22
Reduced
17
Closed
9
Calls
$2.16​M
Puts
$2.29​M
Net Calls
-⁠$134​K
Net Calls Change
-⁠$447​K

TTPH Hedge Fund Activity: Q3 2014 in Review

73 of the 3,454 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals (TTPH) for Q3 2014, worth a combined $286M — up 54% from $185M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new TTPH positions and 9 closed out — a net gain of 8 holders — while 22 added to existing stakes and 17 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $6.76M. The largest seller was Broadfin Capital, cutting an estimated $15.5M.

  • 73 institutional investors held Tetraphase Pharmaceuticals (TTPH) as of Q3 2014, up from 64 in Q2 2014.
  • Funds reported $286M of Tetraphase Pharmaceuticals stock for Q3 2014, up 54% quarter-over-quarter.
  • 17 funds opened new Tetraphase Pharmaceuticals positions in Q3 2014 and 9 closed out, a net change of +8 holders.
  • The largest Tetraphase Pharmaceuticals buyer in Q3 2014 was Adage Capital Partners, an estimated $6.76M added.
  • The largest Tetraphase Pharmaceuticals seller in Q3 2014 was Broadfin Capital, an estimated $15.5M sold.

Based on aggregated 13F filings for Q3 2014.